First Investment: 2021
Finding new drugs to treat disease requires understanding the exact changes in gene and protein expression that make patients sick. Relation Therapeutics is using active graph machine learning, a mathematical method adapted from consumer social networking, to study data from individual human cells to find the most promising ways to treat disease, starting with osteoporosis.
News & Insights
Deep Tech Opportunities Report
Deep Tech Opportunities Report
DCVC DTOR 2024: TechBio is emerging as the data-centric, AI-native counterweight to biotech
News
Relation Therapeutics partners with GSK in history-making collaboration to create new treatments for fibrosis and osteoarthritis
Deep Tech Opportunities Report
DCVC DTOR 2024: In the AI race, data will emerge as the critical asset
News
DCVC leads $35 million financing to help UK TechBio leader Relation Therapeutics to seek new treatments for complex diseases
In The Media
Forbes
How Collaborations Are Helping London Biotechs Find A Route To Market
Relation
Endpoints News
'It's the biology, stupid': Relation and GSK team up on fibrosis, osteoarthritis
Relation
Endpoints News
‘ChatGPT for DNA’: Relation nabs $35M, with Nvidia backing, for osteoporosis work
Relation
Clarivate
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
Relation
Explore Companies
Newleos Therapeutics
Transforming the treatment of anxiety and other neuropsychiatric disorders
Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs